Myasthenic crisis is a complication of myasthenia gravis characterized by worsening of muscle weakness, resulting in respiratory failure that requires intubation and mechanical ventilation. Advances in critical care have improved the mortality rate associated with myasthenic crisis. This article reviews the epidemiology of myasthenic crisis and discusses patient evaluation. Therapeutic options including mechanical ventilation and pharmacological and surgical treatments are also discussed.
RopperAHGressDRDiringerMNGreenDMMayerSABleckTP.Treatment of the Critically Ill Patient With Myasthenia Gravis. Neurological and Neurosurgical Intensive Care. 4th ed.Philadelphia, PA: Lipincott Williams & Wilkins; 2004:299–311.
VincentALeiteMI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol. 2005;18:519–525.
5.
BedlackRSSandersDB. On the concept of myasthenic crisis. J Clin Neuromuscul Dis. 2002;4:40–42.
6.
ThomasCEMayerSAGungorY. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48:1253–1260.
7.
RabinsteinAAMueller-KronastN. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care. 2005;3:213–215.
8.
O’RiordanJIMillerDHMottersheadJPHirschNPHowardRS. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol. 1998;5:137–142.
9.
AlshekhleeAMilesJDKatirjiBPrestonDCKaminskiHJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72:1548–1554.
10.
CohenMSYoungerD. Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci. 1981;377:670–677.
11.
JuelVC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004;24:75–81.
12.
Mier-JedrzejowiczAKBrophyCGreenM. Respiratory muscle function in myasthenia gravis. Am Rev Respir Dis. 1988;138:867–873.
13.
AhmedSKirmaniJFJanjuaN. An update on myasthenic crisis. Curr Treat Options Neurol. 2005 Mar;7(2):129–141.
14.
RabinsteinAAWijdicksEF. Warning signs of imminent respiratory failure in neurological patients. Semin Neurol. 2003;23:97–104.
RiederPLouisMJollietPChevroletJC. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med. 1995;21:663–668.
17.
PutmanMTWiseRA. Myasthenia gravis and upper airway obstruction. Chest. 1996;109:400–404.
BarakaA. Anaesthesia and myasthenia gravis. Can J Anaesth. 1992;39:476–486.
20.
MeriggioliMN. Myasthenia gravis: immunopathogenesis, diagnosis, and management. Continuum: Lifelong Learning in Neurology. 2009;15:35–62.
21.
SeneviratneJMandrekarJWijdicksEFRabinsteinAA. Predictors of extubation failure in myasthenic crisis. Arch Neurol. 2008;65:929–933.
22.
WuJYKuoPHFanPCWuHDShihFYYangPC. The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis. Neurocrit Care. 2009;10:35–42.
23.
VarelasPNChuaHCNattermanJ. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med. 2002;30:2663–2668.
24.
SeneviratneJMandrekarJWijdicksEFRabinsteinAA. Noninvasive ventilation in myasthenic crisis. Arch Neurol. 2008;65:54–58.
25.
RabinsteinAWijdicksEF. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation. Neurology. 2002;59:1647–1649.
26.
KeeseyJC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004;29:484–505.
27.
WeismanSJ. Masked myasthenia gravis. J Am Med Assoc. 1949;141:917.
28.
DrachmanDASkomJH. Procainamide—a hazard in myasthenia gravis. Arch Neurol. 1965;13:316–320.
RajasekaranDChandrasekarSRajendranM. Drug related crisis in myasthenia gravis. J Assoc Physicians India. 2006;54:820–821.
31.
Pina LatorreMACobetaJCRodillaFNavarroNZabalaS. Influence of calcium antagonist drugs in myasthenia gravis in the elderly. J Clin Pharm Ther. 1998;23:399–401.
32.
SwashMIngramDA. Adverse effect of verapamil in myasthenia gravis. Muscle Nerve. 1992;15:396–398.
33.
BashukRGKrendelDA. Myasthenia gravis presenting as weakness after magnesium administration. Muscle Nerve. 1990;13:708–712.
34.
ArgovZBrennerTAbramskyO. Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol. 1986;43:255–256.
35.
TordaT. The nature of gentamicin-induced neuromuscular block. Br J Anaesth. 1980;52:325–329.
36.
HokkanenE. Antibiotics in myasthenia gravis. Br Med J. 1964;1:1111–1112.
37.
MumfordCJGinsbergL. Ciprofloxacin and myasthenia gravis. Br Med J. 1990;301:818.
38.
MayEFCalvertPC. Aggravation of myasthenia gravis by erythromycin. Ann Neurol. 1990;28:577–579.
39.
BrumlikJJacobsRS. Myasthenia gravis associated with diphenylhydantoin therapy for epilepsy. Can J Neurol Sci. 1974;1:127–129.
40.
ScheschonkaABeucheW. Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. Pain. 2003;104:423–424.
41.
KurodaYEndoCNeshigeRKakigiR. Exacerbation of myasthenia gravis shortly after administration of methimazole for hyperthyroidism. Jpn J Med. 1991;30:578–581.
42.
KonishiT. A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C [in Japanese]. Rinsho Shinkeigaku. 1996;36:980–985.
43.
EliashivSWirguinIBrennerTArgovZ. Aggravation of human and experimental myasthenia gravis by contrast media. Neurology. 1990;40:1623–1625.
44.
PascuzziRMCoslettHBJohnsTR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15:291–298.
45.
BaeJSGoSMKimBJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006;13:1006–1010.
46.
YoungerDSRaksadawanN. Therapy in neuromuscular disease. Neurol Clin. 2001;19:205–215, vii.
47.
BertoriniTENanceAMHornerLHGreeneWGelfandMSJasterJH. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve. 1996;19:388–391.
48.
GrilloJAGorsonKCRopperAHLewisJWeinsteinR. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology. 2001;57:1699–1701.
49.
SheminDBriggsDGreenanM. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22:270–276.
50.
RodnitzkyRLGoekenJA. Complications of plasma exchange in neurological patients. Arch Neurol. 1982;39:350–354.
51.
GoldRSchneider-GoldC. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics. 2008;5:535–541.
52.
StrickerRBKwiatkowskaBJHabisJAKiprovDD. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol. 1993;50:837–840.
53.
QureshiAIChoudhryMAAkbarMS. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52:629–632.
54.
GajdosPChevretSClairBTranchantCChastangC. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789–796.
55.
BerrouschotJBaumannIKalischewskiPSterkerMSchneiderD. Therapy of myasthenic crisis. Crit Care Med. 1997;25:1228–1235.
56.
MayerSAThomasCE. Therapy of myasthenic crisis. Crit Care Med. 1998;26:1136–1137.
57.
GronsethGSBarohnRJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:7–15.
58.
SoleimaniAMoayyeriAAkhondzadehSSadatsafaviMTavakoli ShalmaniHSoltanzadehA. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. BMC Neurol. 2004;4:12.
KasJKissDSimonVSvasticsEMajorLSzoborA. Decade-long experience with surgical therapy of myasthenia gravis: early complications of 324 transsternal thymectomies. Ann Thorac Surg. 2001;72:1691–1697.
61.
WatanabeAWatanabeTObamaT. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg. 2004;127:868–876.
